US20070198080A1 - Coatings including an antioxidant - Google Patents

Coatings including an antioxidant Download PDF

Info

Publication number
US20070198080A1
US20070198080A1 US11/528,891 US52889106A US2007198080A1 US 20070198080 A1 US20070198080 A1 US 20070198080A1 US 52889106 A US52889106 A US 52889106A US 2007198080 A1 US2007198080 A1 US 2007198080A1
Authority
US
United States
Prior art keywords
medical device
rapamycin
coating
sodm
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/528,891
Inventor
Ni Ding
Leslie Coleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Cardiovascular Systems Inc
Original Assignee
Abbott Cardiovascular Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/189,216 priority Critical patent/US7785647B2/en
Application filed by Abbott Cardiovascular Systems Inc filed Critical Abbott Cardiovascular Systems Inc
Priority to US11/528,891 priority patent/US20070198080A1/en
Assigned to ABBOTT CARDIOVASCULAR SYSTEMS INC. reassignment ABBOTT CARDIOVASCULAR SYSTEMS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DING, NI, COLEMAN, LESLIE
Publication of US20070198080A1 publication Critical patent/US20070198080A1/en
Priority claimed from US12/485,756 external-priority patent/US8394446B2/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/13Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1303Paper containing [e.g., paperboard, cardboard, fiberboard, etc.]
    • Y10T428/1307Bag or tubular film [e.g., pouch, flexible food casing, envelope, etc.]

Abstract

A coating including an antioxidant or a combination of antioxidant and another bioactive agent on a medical device is described.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This is a continuation-in-part application of U.S. application Ser. No. 11/189,216, filed on Jul. 25, 2005, the teachings of which are incorporated hereto by reference.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention generally relates to a method of providing an antioxidant to a coating on a medical device such as a drug-delivery stent.
  • 2. Description of the Background
  • Blood vessel occlusions are commonly treated by mechanically enhancing blood flow in the affected vessels, such as by employing a stent. Stents are used not only for mechanical intervention but also as vehicles for providing biological therapy. To effect a controlled delivery of an active agent in stent medication, the stent can be coated with a biocompatible polymeric coating. The biocompatible polymeric coating can function either as a permeable layer or a carrier to allow a controlled delivery of the agent.
  • Although stents work well mechanically, the chronic issues of restenosis and, to a lesser extent, stent thrombosis remain. Pharmacological therapy in the form of a drug delivery stent appears to be a feasible means to tackle these issues. Subacute thrombosis and neointimal hyperplasia are considered to be the leading complications after stenting. Various factors are believed to be involved in the process. Methods for reducing thrombosis and restenosis have been previously proposed. However, those methods are less satisfactory for reducing thrombosis or restenosis associated with stenting.
  • The embodiments disclosed herein address the above described problems.
  • SUMMARY OF THE INVENTION
  • Provided herein is a coating that includes an antioxidant for a medical device. The coating includes a polymer matrix, an antioxidant, and optionally heparin or a bioactive agent. In some embodiments, the coating can include a biobeneficial material. The coating can be biodegradable or nondegradable. In some embodiments, the medical device can be a stent. In some embodiments, the stent, itself, can be a polymeric biodegradable, bioerodable or bioabsorbable stent, terms which are used interchangeably unless specifically indicated, which can include the bioactive agent embedded in the body of the stent or coating in the stent.
  • In some embodiments, the antioxidant can be embedded within the coating of the body of the medical device. In some embodiments, the antioxidant can be attached to the surface of the coating or surface of the medical device.
  • In some embodiments, a coating or device can include two ore more antioxidants, at least one of the antioxidant can be butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), Vitamin E, a super-oxide dismutase mimetic (SODm), or combinations thereof.
  • Some examples of the bioactive agent that can be included in the coating or medical device include, but are not limited to, paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
  • The medical device having the features described herein can be used for treating, preventing, or ameliorating a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
  • DETAILED DESCRIPTION
  • Provided herein is a coating that includes an antioxidant for a medical device. The coating includes a polymer matrix, an antioxidant, and optionally heparin or a bioactive agent. In some embodiments, the coating can include a biobeneficial material. The coating can be biodegradable or nondegradable. In some embodiments, the medical device can be a stent. In some embodiments, the stent, itself, can be a polymeric biodegradable, bioerodable or bioabsorbable stent, terms which are used interchangeably unless specifically indicated, which can include the bioactive agent embedded in the body of the stent or coating in the stent.
  • In some embodiments, the antioxidant can be embedded within the coating of the body of the medical device. In some embodiments, the antioxidant can be attached to the surface of the coating or surface of the medical device.
  • In some embodiments, a coating or device can include two ore more antioxidants, at least one of the antioxidant can be BHT, BHA, Vitamin E, a SODm, or combinations thereof.
  • Some examples of the bioactive agent that can be included in the coating or medical device include, but are not limited to, paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
  • The medical device having the features described herein can be used for treating, preventing, or ameliorating a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
  • Antioxidants
  • As used herein, the term “antioxidant” refers to a substance that is capable of inhibiting, preventing, reducing or ameliorating oxidative reactions on another substance (e.g., a polymer, a bioactive agent or a therapeutic substance) when the antioxidant is used in a system (e.g., coating) that includes such other substances. An example of such “antioxidant” is oxygen scavenger.
  • The antioxidant useful in the present invention can be any volatile or non-volatile antioxidant, which can be natural or synthetic. Natural antioxidant refers to an antioxidant derived from a natural source, with or without modification. Synthetic antioxidant refers to any antioxidant that is not a natural antioxidant. For example, ascorbic acid (Vitamin C) can be a natural antioxidant. BHT, BHA, or a SODm can be a synthetic antioxidant.
  • In some embodiments, the antioxidant includes, but is not limited to, BHT, BHA, ascorbic acid (Vitamin C), folic acid, b vitamins, beta carotene, flavonoids, SODm, polyphenol antioxidants such as apigenin or combinations thereof.
  • In some embodiments, the term “antioxidant” can specifically exclude an antioxidant described above. For example, the term “antioxidant” can specifically exclude BHT, BHA or a SODm. In some embodiments, the term “antioxidant” can specifically exclude Vitamin E. In some embodiments, the term “antioxidant” can specifically exclude a super-oxide dismutase mimetic (SODm). In still some embodiments, the antioxidant can specifically exclude one of folic acid, b vitamins, beta carotene, flavonoids, polyphenol antioxidants such as apigenin or combinations thereof.
  • Super-Oxide Dismutase Mimetic
  • In some embodiments, a coating or device can include a super-oxide dismutase (SOD) mimetic (SODm). In some embodiments, the SODm can be attached to the surface of a coating or device. The SODm can be attached to the surface of a coating or device via covalent bonding or non-covalent bonding. Non-covalent bonding can be, e.g., ionic interaction, hydrogen bonding, or an interpenetrating network (IPN).
  • As used herein, the term SODm refers to any super-oxide dismutase (SOD) mimetic. SOD can have important effects on vascular pathophysiology. For example, SOD1-deficient mice have been found to produce more superoxide than their wild-type controls and have decreased endothelium-dependent and -independent vasodilation. SOD1 overexpression in mice causes a decrease in VSMC proliferation in response to EGF but no change in the aortic hypertrophic response to Angiotensin II. A separate study with mice overexpressing SOD1 on the apoE−/− background showed no significant effect on aortic atherosclerotic lesion area. Total SOD2 deficiency is lethal in mice, and although partial SOD2 deficiency has been shown to cause an increase in atherosclerotic lesion formation at arterial branch points, there was no effect on vasomotor responses to serotonin, PGF2α, or acetylcholine at baseline or after inhibition of SOD1 and SOD3 with diethyldithiocarbamate. The second most abundant SOD isoform in blood vessels is SOD3, which is predominantly produced by VSMCs, but because of its location in the interstitium between ECs and VSMCs, it is thought to be essential for endothelial-dependent vasodilation by protecting NO as it diffuses from the ECs to the VSMCs. These differences in the regulation of vascular tone or in the formation of atherosclerotic lesions indicate the potential importance of the subcellular localization of antioxidant systems in the modulation of local oxidant signaling.
  • Some examples of SODm include, but are not limited to, low molecular weight SOD synzymes having a Mn(II) coordinated in a macrocyclic pentamine ring (Ref: Riley D P, Weiss R H. JACS 1994; 116:387-388). In some embodiments, a coating or device can specifically exclude a SODm described above.
  • A SODm can be included in the coating or device or attached to the surface of a coating or device with or without a spacer. Attaching a SODm to the surface of a coating or device can be achieved by, for example, attaching the SODm to a polymer on the surface of the coating or the device via coupling of the reactive group in the SODm molecule to the polymer. In some embodiments, attaching a SODm to the polymer can be achieved by photo or thermally initiated radical coupling, which are well known in the art. In some embodiments, covalent attachment of a SODm to a polymer in the coating can be accomplished for example by reacting isocyanate group on the polymer chain with amino group on SODm (ref. Udipi, K, et al. J. biomaterial Mater. Res., 51, 549-560, 2000).
  • In some embodiments, attachment of a SODm to the polymer can be induced via photo activation. For example, photo-reactive chemical(s) (PRC) can extract hydrogen on the surface in the form of C—H or Si—H bonds, and covalently couple directly to the surface. If the PRC contains chemically reactive groups, a SODm, can be bound to the PRC. As a result, a SODm can be covalently grafted to the carbon surface.
  • Examples of photo-reactive chemicals are from the benzophenone family, i.e. benzophenone tetracarboxylic dianhydride, benzoylbenzoic acid, benzoyl benzoyl chloride, 4-benzoylbenzoic acid N-hydroxysuccinimide ester, benzoyl benzoyl amine, or from azide family, i.e. substituted phenyl azide and substituted acyl azide.
  • The hydrogen extraction can be initiated by UV exposure of the PRC entity. The linking reaction between PRC to the SODm will be dependent on the specific structure of the molecule but can be readily carried out by an ordinary artisan. For example, an amine functional group on SODm can react with an anhydride or acyl chloride of substituted benzophenone. The PRC can be coupled to the carbon surface first and then coupled with the SODm, or vice versa.
  • In some embodiments, a SODm can be attached to a polymer to form a SODm/polymer conjugate. The SODm/polymer conjugate can then be included in a formulation for forming a coating or a device. The SODm/polymer conjugate can have a covalent bond or non-covalent bond between the SODm and the polymer.
  • In some embodiments, antioxidants can be susceptible to oxidation or chemical changes under certain conditions. For example, BHT and BHA at an elevated temperature can compromise the molecular integrity of the antioxidant or cause an volatile antioxidant to evaporate. Therefore, the conditions in the coating process or device forming process can affect the content of the antioxidant to minimize the reduction of the level of antioxidant.
  • In some embodiments, the loss of antioxidant(s) in the coating or device forming process can be reduced by controlling the processing conditions. Such control of processing conditions can be, e.g., duration of the process, exclusion of air or oxygen using inert atmosphere or lowering the processing temperature. In some embodiments, the sterilization process can be conducted at a low temperature. A low temperature of sterilization refers to a temperature from about 25° C. to about 55° C., e.g., from about 30° C. to about 45° C. In some embodiments, the baking process can be conducted at a low temperature or in vacuum. A low temperature of baking refers to a temperature from about 25° C. to about 55° C. with and without vacumm. The procedure or process of coating or forming a medical device including stent is well documented in the art.
  • In some embodiments, the content of the antioxidant in a coating or device can be maintained or enhanced by adding an additional amount of the antioxidant (e.g., BHT or BHA) in the formulation forming the coating or device. Such additional amount depends from the chemical, physical or physiological nature of the antioxidant. For example, in the coating formulation, the BHT level can be increased up to about 60 wt %. Other types of antioxidant such as vitamin C can have a level from about 60 wt %. If a coating already contains an active agent, the antioxidant can be added as a second active agent in the coating at an amount that can be up to about 50 wt %. The active agent can be, e.g., paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor-cell-capturing antibody, or combinations thereof.
  • Biocompatible Polymers
  • A coating or device having an antioxidant described herein can include one or more biocompatible polymer(s). The biocompatible polymer can be biodegradable (bioerodable or bioabsorbable) or nondegradable. Representative biocompatible polymers include, but are not limited to, poly(ester amide), polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(3-hydroxyheptanoate) and poly(3-hydroxyoctanoate), poly(4-hydroxyalkanaote) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanote), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers described herein or blends thereof, poly(D,L-lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(dioxanone), poly(ortho esters), poly(anhydrides), poly(tyrosine carbonates) and derivatives thereof, poly(tyrosine ester) and derivatives thereof, poly(imino carbonates), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride, polyvinyl ethers, such as polyvinyl methyl ether, polyvinylidene halides, such as polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, polycarbonates, polyoxymethylenes, polyimides, polyethers, poly(glyceryl sebacate), poly(propylene fumarate), poly(n-butyl methacrylate), poly(sec-butyl methacrylate), poly(isobutyl methacrylate), poly(tert-butyl methacrylate), poly(n-propyl methacrylate), poly(isopropyl methacrylate), poly(ethyl methacrylate), poly(methyl methacrylate), epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, carboxymethyl cellulose, polyethers such as poly(ethylene glycol) (PEG), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as HEMA, hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as collagen, chitosan, alginate, fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, or combinations thereof. In some embodiments, the coating or device described herein can exclude any one of the aforementioned polymers.
  • As used herein, the terms poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-glycolide), and poly(L-lactide-co-glycolide) can be used interchangeably with the terms poly(D,L-lactic acid), poly(L-lactic acid), poly(D,L-lactic acid-co-glycolic acid), or poly(L-lactic acid-co-glycolic acid), respectively.
  • In some embodiments, the coating or device can include a fluoropolymer such as a Solef™ polymer (e.g., PVDF-HFP).
  • In some embodiments, the coating or device can further include a biobeneficial material. The biobeneficial material can be polymeric or non-polymeric. The biobeneficial material is preferably substantially non-toxic, non-antigenic and non-immunogenic. A biobeneficial material is one that enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
  • Representative biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, poly(ethylene glycol) acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, hyaluronic acid, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, silicones, PolyActive™, and combinations thereof. In some embodiments, the coating or device can exclude any one of the aforementioned polymers.
  • The term PolyActive™ refers to a block copolymer having flexible poly(ethylene glycol) and poly(butylene terephthalate) blocks (PEGT/PBT). PolyActive™ is intended to include AB, ABA, BAB copolymers having such segments of PEG and PBT (e.g., poly(ethylene glycol)-block-poly(butyleneterephthalate)-block poly(ethylene glycol) (PEG-PBT-PEG).
  • In a preferred embodiment, the biobeneficial material can be a polyether such as poly(ethylene glycol) (PEG) or polyalkylene oxide.
  • Above listed polymers can be used as a drug carrier for active agents or topcoat to control the drug release. Alternatively, one active agent (such as antioxidant) can be imbedded in one biocompatible coating and another active agent (anti-proliferative agent) can be coated with the polymer on the top of the layer or vice versa.
  • Bioactive Agents
  • In some embodiments, the coating or device having the features described herein can include one or more bioactive agents. The bioactive agents can be any bioactive agent that is therapeutic, prophylactic, or diagnostic. These agents can have anti-proliferative or anti-inflammatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, and antioxidant properties. These agents can be cystostatic agents, agents that promote the healing of the endothelium such as NO releasing or generating agents, agents that attract endothelial progenitor cells, or agents that promote the attachment, migration and proliferation of endothelial cells (e.g., natriuretic peptide such as CNP, ANP or BNP peptide or an RGD or cRGD peptide), while quenching smooth muscle cell proliferation. Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules that bind to complementary DNA to inhibit transcription, and ribozymes. Some other examples of other bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Examples of anti-proliferative agents include rapamycin and its functional or structural derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), and its functional or structural derivatives, paclitaxel and its functional and structural derivatives. Examples of rapamycin derivatives include methyl rapamycin (ABT-578), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin. Examples of paclitaxel derivatives include docetaxel. Examples of antineoplastics or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ib/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), nitric oxide or nitric oxide donors, super oxide dismutases, super oxide dismutase mimetic, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), estradiol, anticancer agents, dietary supplements such as various vitamins, and a combination thereof. Examples of anti-inflammatory agents including steroidal and non-steroidal anti-inflammatory agents include tacrolimus, dexamethasone, clobetasol, combinations thereof. Examples of such cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.). An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents that may be appropriate include alpha-interferon, pimecrolimus, imatinib mesylate, midostaurin, bioactive RGD, and genetically engineered endothelial cells. The foregoing substances can also be used in the form of prodrugs or co-drugs thereof. The foregoing substances also include metabolites thereof or prodrugs of the metabolites. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents that are currently available or that may be developed in the future are equally applicable.
  • The dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the bioactive agent can depend upon factors such as the particular circumstances of the patient, the nature of the trauma, the nature of the therapy desired, the time over which the ingredient administered resides at the vascular site, and if other active agents are employed, the nature and type of the substance or combination of substances. Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
  • Examples of Medical Device
  • As used herein, a medical device may be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such medical devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), heart valve prostheses, cerebrospinal fluid shunts, pacemaker electrodes, catheters, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.), anastomotic devices and connectors, orthopedic implants such as screws, spinal implants, and electro-stimulatory devices. The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable (e.g., bioabsorbable stent) or biostable polymers could also be used with the embodiments of the present invention.
  • Method of Use
  • Preferably, the medical device is a stent. The stent described herein is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating diseased regions of blood vessels caused by lipid deposition, monocyte or macrophage infiltration, or dysfunctional endothelium or a combination thereof, or occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, carotid and coronary arteries.
  • For implantation of a stent, an angiogram is first performed to determine the appropriate positioning for stent therapy. An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter that allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously or by surgery into the femoral artery, radial artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having the above-described coating may then be expanded at the desired area of treatment. A post-insertion angiogram may also be utilized to confirm appropriate positioning.
  • While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

Claims (51)

1. A medical device comprising a coating, the coating comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof,
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and
wherein the natural antioxidant is not Vitamin E.
2. The medical device of claim 1, wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
3. The medical device of claim 2, wherein the SODm is attached to the surface of the coating.
4. The medical device of claim 3, wherein the SODm is attached to a polymer in the coating.
5. The medical device of claim 1, wherein the coating further comprises a bioactive agent.
6. The medical device of claim 1, wherein the coating further comprises heparin.
7. The medical device of claim 5, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
8. The medical device of claim 1, which is a stent.
9. The medical device of claim 1, which is a bioabsorbable stent.
10. The medical device of claim 1, wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
11. A bioabsorbable medical device comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof,
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and
wherein the natural antioxidant is not Vitamin E.
12. The bioabsorbable medical device of claim 11, wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
13. The bioabsorbable medical device of claim 11, wherein the SODm is attached to the surface of the bioabsorbable medical device.
14. The bioabsorbable medical device of claim 11, wherein the bioabsorbable medical device further comprises a bioactive agent.
15. The bioabsorbable medical device of claim 11, wherein the bioabsorbable medical device further comprises heparin.
16. The medical device of claim 14, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
17. The bioabsorbable medical device of claim 11, which is a stent.
18. The bioabsorbable medical device of claim 11, wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
19. A method comprising
applying to a medical device a formulation comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof, and
forming a coating of the formulation on the medical device,
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA),
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and
wherein the natural antioxidant is not Vitamin E.
20. The method of claim 19, wherein the antioxidant is selected from ascorbic acid, folic acid and B vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
21. The method of claim 20, wherein the SODm is attached to the surface of the coating.
22. The method of claim 20, wherein the SODm is attached to a polymer in the coating.
23. The method of claim 19, wherein the formulation further comprises a bioactive agent.
24. The method of claim 19, wherein the formulation further comprises heparin.
25. The method of claim 24, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate; midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
26. The method of claim 19, wherein the medical device is a stent.
27. The method of claim 19, wherein the medical device is a bioabsorbable stent.
27. The method of claim 19, wherein forming the coating comprises
baking the coating, and
sterilizing the coating.
28. The method of claim 27, wherein the baking or sterilizing are conducted at a temperature between about 25° C. and about 55° C.
29. The method of claim 20, wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
30. A method comprising implanting the medical device of claim 1 into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
31. A method, comprising implanting the medical device of claim 7 to the human being, into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
32. A method comprising implanting the medical device of claim 8 into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
33. A medical device comprising a coating, the coating comprising at least two antioxidants, wherein one antioxidant is selected from BHT, BHA, Vitamin E, a SODm or a combination thereof.
34. The medical device of claim 33, wherein the other antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, polyphenol antioxidants, apigenin or combinations thereof.
35. The medical device of claim 33, wherein the SODm is attached to the surface of the coating.
36. The medical device of claim 35, wherein the SODm is attached to a polymer in the coating.
37. The medical device of claim 33, wherein the coating further comprises a bioactive agent.
38. The medical device of claim 33, wherein the coating further comprises heparin.
39. The medical device of claim 37, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
40. The medical device of claim 33, which is a stent.
41. The medical device of claim 33, which is a bioabsorbable stent.
42. The medical device of claim 33, wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
43. A bioabsorbable medical device comprising at least two antioxidants, wherein one antioxidant is selected from BHT, BHA, Vitamin E, a SODm or a combination thereof.
44. The bioabsorbable medical device of claim 43, wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
45. The bioabsorbable medical device of claim 43, wherein the SODm is attached to the surface of the bioabsorbable medical device.
46. The bioabsorbable medical device of claim 43, wherein the bioabsorbable medical device further comprises a bioactive agent.
47. The bioabsorbable medical device of claim 43, wherein the bioabsorbable medical device further comprises heparin.
48. The medical device of claim 46, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
49. The bioabsorbable medical device of claim 43, which is a stent.
50. The bioabsorbable medical device of claim 43, wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
US11/528,891 2005-07-25 2006-09-27 Coatings including an antioxidant Abandoned US20070198080A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/189,216 US7785647B2 (en) 2005-07-25 2005-07-25 Methods of providing antioxidants to a drug containing product
US11/528,891 US20070198080A1 (en) 2005-07-25 2006-09-27 Coatings including an antioxidant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/528,891 US20070198080A1 (en) 2005-07-25 2006-09-27 Coatings including an antioxidant
US12/485,756 US8394446B2 (en) 2005-07-25 2009-06-16 Methods of providing antioxidants to implantable medical devices
US13/759,898 US9655751B2 (en) 2005-07-25 2013-02-05 Kits including implantable medical devices and antioxidants
US13/760,540 US20130145729A1 (en) 2005-07-25 2013-02-06 Methods of Providing Antioxidants to Implantable Medical Devices

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/189,216 Continuation-In-Part US7785647B2 (en) 2005-07-25 2005-07-25 Methods of providing antioxidants to a drug containing product

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/189,216 Continuation-In-Part US7785647B2 (en) 2005-07-25 2005-07-25 Methods of providing antioxidants to a drug containing product
US12/485,756 Continuation-In-Part US8394446B2 (en) 2005-07-25 2009-06-16 Methods of providing antioxidants to implantable medical devices

Publications (1)

Publication Number Publication Date
US20070198080A1 true US20070198080A1 (en) 2007-08-23

Family

ID=37679362

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/189,216 Active 2028-02-05 US7785647B2 (en) 2005-07-25 2005-07-25 Methods of providing antioxidants to a drug containing product
US11/528,891 Abandoned US20070198080A1 (en) 2005-07-25 2006-09-27 Coatings including an antioxidant
US12/851,414 Abandoned US20100300917A1 (en) 2005-07-25 2010-08-05 Methods of providing antioxidants to a drug containing product
US12/851,420 Active 2028-05-13 US9675737B2 (en) 2005-07-25 2010-08-05 Methods of providing antioxidants to a drug containing product

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/189,216 Active 2028-02-05 US7785647B2 (en) 2005-07-25 2005-07-25 Methods of providing antioxidants to a drug containing product

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/851,414 Abandoned US20100300917A1 (en) 2005-07-25 2010-08-05 Methods of providing antioxidants to a drug containing product
US12/851,420 Active 2028-05-13 US9675737B2 (en) 2005-07-25 2010-08-05 Methods of providing antioxidants to a drug containing product

Country Status (2)

Country Link
US (4) US7785647B2 (en)
WO (1) WO2007018931A2 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080114096A1 (en) * 2006-11-09 2008-05-15 Hydromer, Inc. Lubricious biopolymeric network compositions and methods of making same
US20100280594A1 (en) * 2009-05-01 2010-11-04 Medi-Solve, Llc Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
US20100300903A1 (en) * 2005-07-25 2010-12-02 Ni Ding Methods of providing antioxidants to a drug containing product
US20110137407A1 (en) * 2009-07-09 2011-06-09 Thai Minh Nguyen Bare metal stent with drug eluting reservoirs
US8128688B2 (en) * 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US8366660B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US8366662B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20130192167A1 (en) * 2010-09-17 2013-08-01 Terumo Kabushiki Kaisha Silicone rubber composition
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9402935B2 (en) 2006-11-20 2016-08-02 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
RU2606436C2 (en) * 2012-03-13 2017-01-10 ТиссенКрупп Рассельштайн ГмбХ Method for treating steel band or plate provided with metal coating with after-treatment agent, and steel band or plate provided with metal coating
US9655751B2 (en) 2005-07-25 2017-05-23 Abbott Cardiovascular Systems Inc. Kits including implantable medical devices and antioxidants
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9901663B2 (en) 2013-05-06 2018-02-27 Abbott Cardiovascular Systems Inc. Hollow stent filled with a therapeutic agent formulation

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US10076641B2 (en) 2005-05-11 2018-09-18 The Spectranetics Corporation Methods and systems for delivering substances into luminal walls
US20070135909A1 (en) * 2005-12-08 2007-06-14 Desnoyer Jessica R Adhesion polymers to improve stent retention
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8808726B2 (en) * 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
JP2008305262A (en) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc Printer introduction method in server and thin client environment
US20090319031A1 (en) * 2008-06-19 2009-12-24 Yunbing Wang Bioabsorbable Polymeric Stent With Improved Structural And Molecular Weight Integrity
AU2010348988B2 (en) * 2010-03-25 2014-07-03 Lutonix, Inc. Drug releasing coatings for medical devices
EP2380605A1 (en) 2010-04-19 2011-10-26 InnoRa Gmbh Improved formulations for drug-coated medical devices
EP2380604A1 (en) 2010-04-19 2011-10-26 InnoRa Gmbh Improved coating formulations for scoring or cutting balloon catheters
EP2383000A1 (en) 2010-04-19 2011-11-02 InnoRa Gmbh Limus-coated medical devices
US8966868B2 (en) * 2011-05-09 2015-03-03 Abbott Cardiovascular Systems Inc. Methods of stabilizing molecular weight of polymer stents after sterilization
EP2766062B1 (en) 2011-10-14 2015-08-26 Innora GmbH Improved formulations for drug-coated medical devices
WO2013102842A2 (en) 2012-01-06 2013-07-11 Sahajanand Medical Technologies Private Limited Device and composition for drug release
US20140102049A1 (en) * 2012-10-17 2014-04-17 Abbott Cardiovascular Systems Inc. Method Of Fabrication Of Implantable Medical Device Comprising Macrocyclic Triene Active Agent And Antioxidant

Citations (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2072303A (en) * 1932-10-18 1937-03-02 Chemische Forschungs Gmbh Artificial threads, bands, tubes, and the like for surgical and other purposes
US3429717A (en) * 1965-05-24 1969-02-25 Grace W R & Co Flexible film wrapper
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US5100992A (en) * 1989-05-04 1992-03-31 Biomedical Polymers International, Ltd. Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5298260A (en) * 1990-05-01 1994-03-29 Mediventures, Inc. Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5485496A (en) * 1994-09-22 1996-01-16 Cornell Research Foundation, Inc. Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US5610241A (en) * 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5711958A (en) * 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5721131A (en) * 1987-03-06 1998-02-24 United States Of America As Represented By The Secretary Of The Navy Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells
US5723219A (en) * 1995-12-19 1998-03-03 Talison Research Plasma deposited film networks
US5858746A (en) * 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5857998A (en) * 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5865814A (en) * 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5879713A (en) * 1994-10-12 1999-03-09 Focal, Inc. Targeted delivery via biodegradable polymers
US6010530A (en) * 1995-06-07 2000-01-04 Boston Scientific Technology, Inc. Self-expanding endoluminal prosthesis
US6011125A (en) * 1998-09-25 2000-01-04 General Electric Company Amide modified polyesters
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6033582A (en) * 1996-01-22 2000-03-07 Etex Corporation Surface modification of medical implants
US6034204A (en) * 1997-08-08 2000-03-07 Basf Aktiengesellschaft Condensation products of basic amino acids with copolymerizable compounds and a process for their production
US6037022A (en) * 1997-09-16 2000-03-14 International Paper Company Oxygen-scavenging filled polymer blend for food packaging applications
US6042875A (en) * 1997-04-30 2000-03-28 Schneider (Usa) Inc. Drug-releasing coatings for medical devices
US6172167B1 (en) * 1996-06-28 2001-01-09 Universiteit Twente Copoly(ester-amides) and copoly(ester-urethanes)
US6177523B1 (en) * 1999-07-14 2001-01-23 Cardiotech International, Inc. Functionalized polyurethanes
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US20020007213A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020007214A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020007215A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020005206A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Antiproliferative drug and delivery device
US6344035B1 (en) * 1998-04-27 2002-02-05 Surmodics, Inc. Bioactive agent release coating
US6358556B1 (en) * 1995-04-19 2002-03-19 Boston Scientific Corporation Drug release stent coating
US20030004141A1 (en) * 2001-03-08 2003-01-02 Brown David L. Medical devices, compositions and methods for treating vulnerable plaque
US6503556B2 (en) * 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US6503954B1 (en) * 2000-03-31 2003-01-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing actinomycin D and a method of forming the same
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US20030028244A1 (en) * 1995-06-07 2003-02-06 Cook Incorporated Coated implantable medical device
US20030028243A1 (en) * 1995-06-07 2003-02-06 Cook Incorporated Coated implantable medical device
US20030032767A1 (en) * 2001-02-05 2003-02-13 Yasuhiro Tada High-strength polyester-amide fiber and process for producing the same
US20030036794A1 (en) * 1995-06-07 2003-02-20 Cook Incorporated Coated implantable medical device
US6524347B1 (en) * 1997-05-28 2003-02-25 Avantis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US20030039689A1 (en) * 2001-04-26 2003-02-27 Jianbing Chen Polymer-based, sustained release drug delivery system
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US6527801B1 (en) * 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US6527863B1 (en) * 2001-06-29 2003-03-04 Advanced Cardiovascular Systems, Inc. Support device for a stent and a method of using the same to coat a stent
US6530950B1 (en) * 1999-01-12 2003-03-11 Quanam Medical Corporation Intraluminal stent having coaxial polymer member
US6530951B1 (en) * 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US20030060877A1 (en) * 2001-09-25 2003-03-27 Robert Falotico Coated medical devices for the treatment of vascular disease
US20030059520A1 (en) * 2001-09-27 2003-03-27 Yung-Ming Chen Apparatus for regulating temperature of a composition and a method of coating implantable devices
US6673154B1 (en) * 2001-06-28 2004-01-06 Advanced Cardiovascular Systems, Inc. Stent mounting device to coat a stent
US6673385B1 (en) * 2000-05-31 2004-01-06 Advanced Cardiovascular Systems, Inc. Methods for polymeric coatings stents
US20040018296A1 (en) * 2000-05-31 2004-01-29 Daniel Castro Method for depositing a coating onto a surface of a prosthesis
US6689350B2 (en) * 2000-07-27 2004-02-10 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
US6689099B2 (en) * 1999-07-13 2004-02-10 Advanced Cardiovascular Systems, Inc. Local drug delivery injection catheter
US20040029952A1 (en) * 1999-09-03 2004-02-12 Yung-Ming Chen Ethylene vinyl alcohol composition and coating
US6695920B1 (en) * 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US20040047978A1 (en) * 2000-08-04 2004-03-11 Hossainy Syed F.A. Composition for coating an implantable prosthesis
US20040047980A1 (en) * 2000-12-28 2004-03-11 Pacetti Stephen D. Method of forming a diffusion barrier layer for implantable devices
US6706013B1 (en) * 2001-06-29 2004-03-16 Advanced Cardiovascular Systems, Inc. Variable length drug delivery catheter
US20040052858A1 (en) * 2001-05-09 2004-03-18 Wu Steven Z. Microparticle coated medical device
US20040054104A1 (en) * 2002-09-05 2004-03-18 Pacetti Stephen D. Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol)
US6709514B1 (en) * 2001-12-28 2004-03-23 Advanced Cardiovascular Systems, Inc. Rotary coating apparatus for coating implantable medical devices
US6712845B2 (en) * 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
US6713119B2 (en) * 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
US20050004663A1 (en) * 2001-05-07 2005-01-06 Llanos Gerard H. Heparin barrier coating for controlled drug release
US20050037048A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices containing antioxidant and therapeutic agent
US20050037052A1 (en) * 2003-08-13 2005-02-17 Medtronic Vascular, Inc. Stent coating with gradient porosity
US20050038134A1 (en) * 1997-08-18 2005-02-17 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US20050038497A1 (en) * 2003-08-11 2005-02-17 Scimed Life Systems, Inc. Deformation medical device without material deformation
US20050043786A1 (en) * 2003-08-18 2005-02-24 Medtronic Ave, Inc. Methods and apparatus for treatment of aneurysmal tissue
US6861088B2 (en) * 2002-03-28 2005-03-01 Boston Scientific Scimed, Inc. Method for spray-coating a medical device having a tubular wall such as a stent
US20050049693A1 (en) * 2003-08-25 2005-03-03 Medtronic Vascular Inc. Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease
US20050049694A1 (en) * 2003-08-07 2005-03-03 Medtronic Ave. Extrusion process for coating stents
US20050054774A1 (en) * 2003-09-09 2005-03-10 Scimed Life Systems, Inc. Lubricious coating
US20050055044A1 (en) * 2003-09-09 2005-03-10 Scimed Life Systems, Inc. Lubricious coatings for medical device
US20050055078A1 (en) * 2003-09-04 2005-03-10 Medtronic Vascular, Inc. Stent with outer slough coating
US6865810B2 (en) * 2002-06-27 2005-03-15 Scimed Life Systems, Inc. Methods of making medical devices
US20050060020A1 (en) * 2003-09-17 2005-03-17 Scimed Life Systems, Inc. Covered stent with biologically active material
US6869443B2 (en) * 1991-10-04 2005-03-22 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US20050065501A1 (en) * 2003-09-23 2005-03-24 Scimed Life Systems, Inc. Energy activated vaso-occlusive devices
US20050064088A1 (en) * 2003-09-24 2005-03-24 Scimed Life Systems, Inc Ultrasonic nozzle for coating a medical appliance and method for using an ultrasonic nozzle to coat a medical appliance
US20050065593A1 (en) * 2003-09-19 2005-03-24 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US20050065545A1 (en) * 2003-09-23 2005-03-24 Scimed Life Systems, Inc. External activation of vaso-occlusive implants

Family Cites Families (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386454A (en) 1940-11-22 1945-10-09 Bell Telephone Labor Inc High molecular weight linear polyester-amides
US3849514A (en) 1967-11-17 1974-11-19 Eastman Kodak Co Block polyester-polyamide copolymers
US3993622A (en) 1970-10-08 1976-11-23 Ciba-Geigy Corporation Bis-salicyloyl-hydrazine as stabilizer for polymers
US3773737A (en) 1971-06-09 1973-11-20 Sutures Inc Hydrolyzable polymers of amino acid and hydroxy acids
US4329383A (en) 1979-07-24 1982-05-11 Nippon Zeon Co., Ltd. Non-thrombogenic material comprising substrate which has been reacted with heparin
SU790725A1 (en) 1979-07-27 1983-01-23 Ордена Ленина Институт Элементоорганических Соединений Ан Ссср Process for preparing alkylaromatic polyimides
US4226243A (en) 1979-07-27 1980-10-07 Ethicon, Inc. Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids
SU811750A1 (en) 1979-08-07 1983-09-23 Институт Физиологии Им.С.И.Бериташвили Bis-bicarbonates of aliphatic diols as monomers for preparing polyurethanes and process for producing the same
SU872531A1 (en) 1979-08-07 1981-10-15 Институт Физиологии Им.И.С.Бериташвили Ан Гсср Method of producing polyurethans
SU876663A1 (en) 1979-11-11 1981-10-30 Институт Физиологии Им. Академика И.С.Бериташвили Ан Гсср Method of producing polyarylates
US4343931A (en) 1979-12-17 1982-08-10 Minnesota Mining And Manufacturing Company Synthetic absorbable surgical devices of poly(esteramides)
SU1016314A1 (en) 1979-12-17 1983-05-07 Институт Физиологии Им.И.С.Бериташвили Process for producing polyester urethanes
US4529792A (en) 1979-12-17 1985-07-16 Minnesota Mining And Manufacturing Company Process for preparing synthetic absorbable poly(esteramides)
SU905228A1 (en) 1980-03-06 1982-02-15 Институт Физиологии Им. Акад.И.С. Бериташвили Ан Гсср Method for preparing thiourea
US4401804A (en) 1982-05-24 1983-08-30 Eastman Kodak Company Deactivation of polyester catalyst residues
US5006281A (en) * 1985-03-26 1991-04-09 Century Laboratories, Inc. Process for the production of a marine animal oil
SU1293518A1 (en) 1985-04-11 1987-02-28 Тбилисский зональный научно-исследовательский и проектный институт типового и экспериментального проектирования жилых и общественных зданий Installation for testing specimen of cross-shaped structure
US4656242A (en) 1985-06-07 1987-04-07 Henkel Corporation Poly(ester-amide) compositions
US4611051A (en) 1985-12-31 1986-09-09 Union Camp Corporation Novel poly(ester-amide) hot-melt adhesives
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
JPH0696023B2 (en) 1986-11-10 1994-11-30 宇部日東化成株式会社 Artificial blood vessel and a method of manufacturing the same
US6387379B1 (en) 1987-04-10 2002-05-14 University Of Florida Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like
US5527337A (en) 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US4894231A (en) 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
JP2561309B2 (en) 1988-03-28 1996-12-04 テルモ株式会社 Medical material and a method of manufacturing the same
US4931287A (en) 1988-06-14 1990-06-05 University Of Utah Heterogeneous interpenetrating polymer networks for the controlled release of drugs
US4977901A (en) 1988-11-23 1990-12-18 Minnesota Mining And Manufacturing Company Article having non-crosslinked crystallized polymer coatings
US5272012A (en) 1989-06-23 1993-12-21 C. R. Bard, Inc. Medical apparatus having protective, lubricious coating
US5455040A (en) 1990-07-26 1995-10-03 Case Western Reserve University Anticoagulant plasma polymer-modified substrate
US5971954A (en) 1990-01-10 1999-10-26 Rochester Medical Corporation Method of making catheter
ES2052369T3 (en) 1990-01-30 1994-07-01 Akzo Nv Article for the controlled delivery of an active substance comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances.
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5306501A (en) 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
US5300295A (en) 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
AU7998091A (en) 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
CA2038605C (en) 1990-06-15 2000-06-27 Leonard Pinchuk Crack-resistant polycarbonate urethane polymer prostheses and the like
JPH05507226A (en) 1990-06-15 1993-10-21
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US5112457A (en) 1990-07-23 1992-05-12 Case Western Reserve University Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants
US6248129B1 (en) 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US5163952A (en) 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
GB9027793D0 (en) 1990-12-21 1991-02-13 Ucb Sa Polyester-amides containing terminal carboxyl groups
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
GB9206736D0 (en) 1992-03-27 1992-05-13 Sandoz Ltd Improvements of organic compounds and their use in pharmaceutical compositions
US5219980A (en) 1992-04-16 1993-06-15 Sri International Polymers biodegradable or bioerodiable into amino acids
DE69325845T2 (en) 1992-04-28 2000-01-05 Terumo Corp The thermoplastic polymer composition and products thereof medical devices
DE4224401A1 (en) 1992-07-21 1994-01-27 Pharmatech Gmbh New biodegradable homo- and co-polymer(s) for pharmaceutical use - produced by polycondensation of prod. from heterolytic cleavage of aliphatic polyester with functionalised (cyclo)aliphatic cpd.
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
FR2699168B1 (en) 1992-12-11 1995-01-13 Rhone Poulenc Chimie A method of processing a material comprising a polymer by hydrolysis.
EP0604022A1 (en) 1992-12-22 1994-06-29 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method for its manufacture
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5824048A (en) 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
JPH0767895A (en) 1993-06-25 1995-03-14 Sumitomo Electric Ind Ltd Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation
EG20321A (en) 1993-07-21 1998-10-31 Otsuka Pharma Co Ltd Medical material and process for producing the same
GB2281161B (en) 1993-08-04 1997-05-28 Fulcrum Communications Limited Optical data communications networks
DE4327024A1 (en) 1993-08-12 1995-02-16 Bayer Ag Thermoplastically processable and biodegradable aliphatic polyesteramides
WO1995010989A1 (en) 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
US5723004A (en) 1993-10-21 1998-03-03 Corvita Corporation Expandable supportive endoluminal grafts
US5759205A (en) 1994-01-21 1998-06-02 Brown University Research Foundation Negatively charged polymeric electret implant
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
US5567410A (en) 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5670558A (en) 1994-07-07 1997-09-23 Terumo Kabushiki Kaisha Medical instruments that exhibit surface lubricity when wetted
US5788979A (en) 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
US5516881A (en) 1994-08-10 1996-05-14 Cornell Research Foundation, Inc. Aminoxyl-containing radical spin labeling in polymers and copolymers
US5578073A (en) 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5649977A (en) 1994-09-22 1997-07-22 Advanced Cardiovascular Systems, Inc. Metal reinforced polymer stent
FR2724938B1 (en) 1994-09-28 1997-02-07
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5569198A (en) 1995-01-23 1996-10-29 Cortrak Medical Inc. Microporous catheter
US5919570A (en) 1995-02-01 1999-07-06 Schneider Inc. Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices
US6017577A (en) 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
US5702754A (en) 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5854376A (en) 1995-03-09 1998-12-29 Sekisui Kaseihin Kogyo Kabushiki Kaisha Aliphatic ester-amide copolymer resins
CA2218495A1 (en) 1995-04-19 1996-10-24 Kazunori Kataoka Heterotelechelic block copolymer and a method for the production thereof
US20020091433A1 (en) 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5667767A (en) 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5658995A (en) 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
DE19545678A1 (en) 1995-12-07 1997-06-12 Goldschmidt Ag Th copolymers Polyaminosäureester
PT876165E (en) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Compositions of reticulated polymers and processes for their use
US5618866A (en) 1996-01-22 1997-04-08 General Electric Company Neo diol phosphite esters and polymeric compositions thereof
US6054553A (en) 1996-01-29 2000-04-25 Bayer Ag Process for the preparation of polymers having recurring agents
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
US5874165A (en) 1996-06-03 1999-02-23 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto polymeric subtrates
SE9602352D0 (en) * 1996-06-14 1996-06-14 Astra Ab catheter package
US6211249B1 (en) 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
US6060518A (en) 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
US5830178A (en) 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US5783657A (en) 1996-10-18 1998-07-21 Union Camp Corporation Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US5997517A (en) 1997-01-27 1999-12-07 Sts Biopolymers, Inc. Bonding layers for medical device surface coatings
AU5932198A (en) 1997-01-28 1998-08-18 United States Surgical Corporation Polyesteramide, its preparation and surgical devices fabricated therefrom
DE69812903T2 (en) 1997-01-28 2003-12-04 United States Surgical Corp Polyesteramide, its production and thus produced surgical devices
EP0960147B1 (en) 1997-01-28 2004-09-29 United States Surgical Corporation Molded surgical device made from polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups
AU6763998A (en) 1997-03-20 1998-10-12 Eastman Chemical Company Process for the modification of a polyester melt used in a continuous melt-to-preform process
US6240616B1 (en) 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6056993A (en) 1997-05-30 2000-05-02 Schneider (Usa) Inc. Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel
US6110483A (en) 1997-06-23 2000-08-29 Sts Biopolymers, Inc. Adherent, flexible hydrogel and medicated coatings
US5980928A (en) 1997-07-29 1999-11-09 Terry; Paul B. Implant for preventing conjunctivitis in cattle
US6121027A (en) 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6120788A (en) 1997-10-16 2000-09-19 Bioamide, Inc. Bioabsorbable triglycolic acid poly(ester-amide)s
US5992000A (en) * 1997-10-16 1999-11-30 Scimed Life Systems, Inc. Stent crimper
US6120491A (en) 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine
CA2312913A1 (en) * 1997-12-12 1999-06-24 Jeffrey C. Way Compounds and methods for the inhibition of protein-protein interactions
US6110188A (en) 1998-03-09 2000-08-29 Corvascular, Inc. Anastomosis method
US6258371B1 (en) 1998-04-03 2001-07-10 Medtronic Inc Method for making biocompatible medical article
US20020051730A1 (en) 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US7658727B1 (en) 1998-04-20 2010-02-09 Medtronic, Inc Implantable medical device with enhanced biocompatibility and biostability
US20020188037A1 (en) 1999-04-15 2002-12-12 Chudzik Stephen J. Method and system for providing bioactive agent release coating
US20020055710A1 (en) 1998-04-30 2002-05-09 Ronald J. Tuch Medical device for delivering a therapeutic agent and method of preparation
US6113629A (en) 1998-05-01 2000-09-05 Micrus Corporation Hydrogel for the therapeutic treatment of aneurysms
KR100314496B1 (en) 1998-05-28 2001-10-30 윤동진 Non-thrombogenic heparin derivatives, process for preparation and use thereof
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
WO2000010622A1 (en) 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6143354A (en) 1999-02-08 2000-11-07 Medtronic Inc. One-step method for attachment of biomolecules to substrate surfaces
AT291446T (en) 1999-05-27 2005-04-15 Monsanto Co Biomaterials modified with superoxide dismutase impersonators
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6494862B1 (en) 1999-07-13 2002-12-17 Advanced Cardiovascular Systems, Inc. Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway
US6759054B2 (en) 1999-09-03 2004-07-06 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol composition and coating
US6287628B1 (en) 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6379381B1 (en) 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6908624B2 (en) 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US20020081228A1 (en) * 1999-12-21 2002-06-27 Hui Henry K. Monitoring sterilant concentration in diffusion-restricted regions as a basis for parametric release
US6613432B2 (en) 1999-12-22 2003-09-02 Biosurface Engineering Technologies, Inc. Plasma-deposited coatings, devices and methods
US6283949B1 (en) 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US20010007083A1 (en) 1999-12-29 2001-07-05 Roorda Wouter E. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
US6899731B2 (en) 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
US20030215564A1 (en) 2001-01-18 2003-11-20 Heller Phillip F. Method and apparatus for coating an endoprosthesis
US6309383B1 (en) 2000-01-20 2001-10-30 Isostent, Inc. Stent crimper apparatus with radiation shied
IT1318423B1 (en) * 2000-03-24 2003-08-25 Great Lakes Chemical Europ The stabilizing mixtures for organic polymers.
US6749626B1 (en) 2000-03-31 2004-06-15 Advanced Cardiovascular Systems, Inc. Actinomycin D for the treatment of vascular disease
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20020022144A1 (en) * 2000-05-19 2002-02-21 Hu Yang Enhanced oxygen barrier performance from modification of ethylene vinyl alcohol copolymers (EVOH)
DE10025458B4 (en) * 2000-05-23 2005-05-12 Vacuumschmelze Gmbh The magnet and the process for its preparation
WO2001090331A2 (en) 2000-05-23 2001-11-29 The Rockefeller University C1 bacteriophage lytic system
US7101624B2 (en) 2000-06-22 2006-09-05 Cello-Foil Products, Inc. Laminate antioxidant film
US6585765B1 (en) 2000-06-29 2003-07-01 Advanced Cardiovascular Systems, Inc. Implantable device having substances impregnated therein and a method of impregnating the same
US6485950B1 (en) * 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
US6555157B1 (en) 2000-07-25 2003-04-29 Advanced Cardiovascular Systems, Inc. Method for coating an implantable device and system for performing the method
US6585926B1 (en) 2000-08-31 2003-07-01 Advanced Cardiovascular Systems, Inc. Method of manufacturing a porous balloon
US6254632B1 (en) 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US20030065377A1 (en) 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US6558733B1 (en) 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US6758859B1 (en) 2000-10-30 2004-07-06 Kenny L. Dang Increased drug-loading and reduced stress drug delivery device
US6727300B2 (en) 2000-11-03 2004-04-27 Cytec Technology Corp. Polymeric articles containing hindered amine light stabilizers based on multi-functional carbonyl compounds
US20020077693A1 (en) 2000-12-19 2002-06-20 Barclay Bruce J. Covered, coiled drug delivery stent and method
US6875400B2 (en) * 2000-12-22 2005-04-05 Cryovac, Inc. Method of sterilizing and initiating a scavenging reaction in an article
US20020082679A1 (en) 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6824559B2 (en) 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
US6544543B1 (en) 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue
US6540776B2 (en) 2000-12-28 2003-04-01 Advanced Cardiovascular Systems, Inc. Sheath for a prosthesis and methods of forming the same
US20020087123A1 (en) 2001-01-02 2002-07-04 Hossainy Syed F.A. Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices
US6645195B1 (en) 2001-01-05 2003-11-11 Advanced Cardiovascular Systems, Inc. Intraventricularly guided agent delivery system and method of use
US6544223B1 (en) 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Balloon catheter for delivering therapeutic agents
US6544582B1 (en) 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Method and apparatus for coating an implantable device
US6740040B1 (en) 2001-01-30 2004-05-25 Advanced Cardiovascular Systems, Inc. Ultrasound energy driven intraventricular catheter to treat ischemia
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
EP1463438A4 (en) 2001-02-09 2008-01-23 Endoluminal Therapeutics Inc Endomural therapy
US6613077B2 (en) 2001-03-27 2003-09-02 Scimed Life Systems, Inc. Stent with controlled expansion
US6623448B2 (en) 2001-03-30 2003-09-23 Advanced Cardiovascular Systems, Inc. Steerable drug delivery device
US6645135B1 (en) 2001-03-30 2003-11-11 Advanced Cardiovascular Systems, Inc. Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance
US6780424B2 (en) 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US6625486B2 (en) 2001-04-11 2003-09-23 Advanced Cardiovascular Systems, Inc. Method and apparatus for intracellular delivery of an agent
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US6660034B1 (en) 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same
US7651695B2 (en) 2001-05-18 2010-01-26 Advanced Cardiovascular Systems, Inc. Medicated stents for the treatment of vascular disease
US6605154B1 (en) 2001-05-31 2003-08-12 Advanced Cardiovascular Systems, Inc. Stent mounting device
US6743462B1 (en) 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US6666880B1 (en) 2001-06-19 2003-12-23 Advised Cardiovascular Systems, Inc. Method and system for securing a coated stent to a balloon catheter
US6572644B1 (en) 2001-06-27 2003-06-03 Advanced Cardiovascular Systems, Inc. Stent mounting device and a method of using the same to coat a stent
US6565659B1 (en) 2001-06-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US6585755B2 (en) 2001-06-29 2003-07-01 Advanced Cardiovascular Polymeric stent suitable for imaging by MRI and fluoroscopy
US6656216B1 (en) 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
EP1273314A1 (en) 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
EP1429689A4 (en) 2001-09-24 2006-03-08 Medtronic Ave Inc Rational drug therapy device and methods
US6753071B1 (en) 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20030073961A1 (en) 2001-09-28 2003-04-17 Happ Dorrie M. Medical device containing light-protected therapeutic agent and a method for fabricating thereof
US7585516B2 (en) 2001-11-12 2009-09-08 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
US6607795B1 (en) 2001-12-19 2003-08-19 Chevron Phillips Chemical Company Lp Oxygen scavenging compositions comprising polymers derived from aromatic difunctional monomers
US6949254B2 (en) 2002-01-30 2005-09-27 Bmg Incorporated Bio-decomposable polymer composition showing good thermal decomposition
US7445629B2 (en) 2002-01-31 2008-11-04 Boston Scientific Scimed, Inc. Medical device for delivering biologically active material
US6746622B2 (en) * 2002-02-08 2004-06-08 Chevron Phillips Chemical Company Lp Oxygen scavenging compositions comprising polymers derived from tetrahydrofurfuryl monomers
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US7022258B2 (en) * 2002-02-14 2006-04-04 Chevron Phillips Chemical Company, Lp Oxygen scavenging compositions comprising polymers derived from benzenedimethanol monomers
JP2003253031A (en) 2002-02-28 2003-09-10 Toray Ind Inc Biodegradable crosslinked resin foam
US8088404B2 (en) 2003-03-20 2012-01-03 Medtronic Vasular, Inc. Biocompatible controlled release coatings for medical devices and related methods
US20030204239A1 (en) 2002-04-26 2003-10-30 Wenda Carlyle Endovascular stent with a preservative coating
DE60303705T2 (en) 2002-05-14 2006-10-19 Terumo K.K. Coated stent for the release of active substances
CN1215156C (en) * 2002-07-12 2005-08-17 吕新 Color-flame candle and method for making same
US6962714B2 (en) 2002-08-06 2005-11-08 Ecolab, Inc. Critical fluid antimicrobial compositions and their use and generation
US20040063805A1 (en) 2002-09-19 2004-04-01 Pacetti Stephen D. Coatings for implantable medical devices and methods for fabrication thereof
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US20070010632A1 (en) 2002-11-27 2007-01-11 Kaplan David L Antioxidant-functionalized polymers
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8801692B2 (en) 2003-09-24 2014-08-12 Medtronic Vascular, Inc. Gradient coated stent and method of fabrication
US7055237B2 (en) 2003-09-29 2006-06-06 Medtronic Vascular, Inc. Method of forming a drug eluting stent
US20050074406A1 (en) 2003-10-03 2005-04-07 Scimed Life Systems, Inc. Ultrasound coating for enhancing visualization of medical device in ultrasound images
US6984411B2 (en) 2003-10-14 2006-01-10 Boston Scientific Scimed, Inc. Method for roll coating multiple stents
US8394446B2 (en) * 2005-07-25 2013-03-12 Abbott Cardiovascular Systems Inc. Methods of providing antioxidants to implantable medical devices
US7785647B2 (en) 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
WO2007050325A2 (en) * 2005-10-24 2007-05-03 Lucite International, Inc. Extrudable acrylic compositions
US8128688B2 (en) * 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US20090319031A1 (en) 2008-06-19 2009-12-24 Yunbing Wang Bioabsorbable Polymeric Stent With Improved Structural And Molecular Weight Integrity
US8207240B2 (en) * 2009-09-14 2012-06-26 Abbott Cardiovascular Systems Inc Method to minimize molecular weight drop of poly(L-lactide) stent during processing

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2072303A (en) * 1932-10-18 1937-03-02 Chemische Forschungs Gmbh Artificial threads, bands, tubes, and the like for surgical and other purposes
US3429717A (en) * 1965-05-24 1969-02-25 Grace W R & Co Flexible film wrapper
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5721131A (en) * 1987-03-06 1998-02-24 United States Of America As Represented By The Secretary Of The Navy Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US5100992A (en) * 1989-05-04 1992-03-31 Biomedical Polymers International, Ltd. Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5298260A (en) * 1990-05-01 1994-03-29 Mediventures, Inc. Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US6869443B2 (en) * 1991-10-04 2005-03-22 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5858746A (en) * 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5857998A (en) * 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5485496A (en) * 1994-09-22 1996-01-16 Cornell Research Foundation, Inc. Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties
US5879713A (en) * 1994-10-12 1999-03-09 Focal, Inc. Targeted delivery via biodegradable polymers
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6358556B1 (en) * 1995-04-19 2002-03-19 Boston Scientific Corporation Drug release stent coating
US5865814A (en) * 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US20030028244A1 (en) * 1995-06-07 2003-02-06 Cook Incorporated Coated implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6010530A (en) * 1995-06-07 2000-01-04 Boston Scientific Technology, Inc. Self-expanding endoluminal prosthesis
US20030036794A1 (en) * 1995-06-07 2003-02-20 Cook Incorporated Coated implantable medical device
US20030028243A1 (en) * 1995-06-07 2003-02-06 Cook Incorporated Coated implantable medical device
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5723219A (en) * 1995-12-19 1998-03-03 Talison Research Plasma deposited film networks
US6033582A (en) * 1996-01-22 2000-03-07 Etex Corporation Surface modification of medical implants
US5610241A (en) * 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US6172167B1 (en) * 1996-06-28 2001-01-09 Universiteit Twente Copoly(ester-amides) and copoly(ester-urethanes)
US5711958A (en) * 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US6530951B1 (en) * 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6042875A (en) * 1997-04-30 2000-03-28 Schneider (Usa) Inc. Drug-releasing coatings for medical devices
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6528526B1 (en) * 1997-05-28 2003-03-04 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6524347B1 (en) * 1997-05-28 2003-02-25 Avantis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6034204A (en) * 1997-08-08 2000-03-07 Basf Aktiengesellschaft Condensation products of basic amino acids with copolymerizable compounds and a process for their production
US20050038134A1 (en) * 1997-08-18 2005-02-17 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6037022A (en) * 1997-09-16 2000-03-14 International Paper Company Oxygen-scavenging filled polymer blend for food packaging applications
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US6344035B1 (en) * 1998-04-27 2002-02-05 Surmodics, Inc. Bioactive agent release coating
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6011125A (en) * 1998-09-25 2000-01-04 General Electric Company Amide modified polyesters
US6530950B1 (en) * 1999-01-12 2003-03-11 Quanam Medical Corporation Intraluminal stent having coaxial polymer member
US6689099B2 (en) * 1999-07-13 2004-02-10 Advanced Cardiovascular Systems, Inc. Local drug delivery injection catheter
US6177523B1 (en) * 1999-07-14 2001-01-23 Cardiotech International, Inc. Functionalized polyurethanes
US6713119B2 (en) * 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
US20040029952A1 (en) * 1999-09-03 2004-02-12 Yung-Ming Chen Ethylene vinyl alcohol composition and coating
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6346110B2 (en) * 1999-10-04 2002-02-12 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implantable device
US6503954B1 (en) * 2000-03-31 2003-01-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing actinomycin D and a method of forming the same
US6527801B1 (en) * 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US20020007213A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020007215A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020005206A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Antiproliferative drug and delivery device
US20020007214A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040018296A1 (en) * 2000-05-31 2004-01-29 Daniel Castro Method for depositing a coating onto a surface of a prosthesis
US6673385B1 (en) * 2000-05-31 2004-01-06 Advanced Cardiovascular Systems, Inc. Methods for polymeric coatings stents
US6689350B2 (en) * 2000-07-27 2004-02-10 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
US20040047978A1 (en) * 2000-08-04 2004-03-11 Hossainy Syed F.A. Composition for coating an implantable prosthesis
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US20040047980A1 (en) * 2000-12-28 2004-03-11 Pacetti Stephen D. Method of forming a diffusion barrier layer for implantable devices
US6503556B2 (en) * 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US20030032767A1 (en) * 2001-02-05 2003-02-13 Yasuhiro Tada High-strength polyester-amide fiber and process for producing the same
US20030004141A1 (en) * 2001-03-08 2003-01-02 Brown David L. Medical devices, compositions and methods for treating vulnerable plaque
US6712845B2 (en) * 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
US20030039689A1 (en) * 2001-04-26 2003-02-27 Jianbing Chen Polymer-based, sustained release drug delivery system
US20050004663A1 (en) * 2001-05-07 2005-01-06 Llanos Gerard H. Heparin barrier coating for controlled drug release
US20040052858A1 (en) * 2001-05-09 2004-03-18 Wu Steven Z. Microparticle coated medical device
US20040052859A1 (en) * 2001-05-09 2004-03-18 Wu Steven Z. Microparticle coated medical device
US6695920B1 (en) * 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US6673154B1 (en) * 2001-06-28 2004-01-06 Advanced Cardiovascular Systems, Inc. Stent mounting device to coat a stent
US6527863B1 (en) * 2001-06-29 2003-03-04 Advanced Cardiovascular Systems, Inc. Support device for a stent and a method of using the same to coat a stent
US6706013B1 (en) * 2001-06-29 2004-03-16 Advanced Cardiovascular Systems, Inc. Variable length drug delivery catheter
US20030060877A1 (en) * 2001-09-25 2003-03-27 Robert Falotico Coated medical devices for the treatment of vascular disease
US20030059520A1 (en) * 2001-09-27 2003-03-27 Yung-Ming Chen Apparatus for regulating temperature of a composition and a method of coating implantable devices
US6709514B1 (en) * 2001-12-28 2004-03-23 Advanced Cardiovascular Systems, Inc. Rotary coating apparatus for coating implantable medical devices
US6861088B2 (en) * 2002-03-28 2005-03-01 Boston Scientific Scimed, Inc. Method for spray-coating a medical device having a tubular wall such as a stent
US6865810B2 (en) * 2002-06-27 2005-03-15 Scimed Life Systems, Inc. Methods of making medical devices
US20040054104A1 (en) * 2002-09-05 2004-03-18 Pacetti Stephen D. Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol)
US20050049694A1 (en) * 2003-08-07 2005-03-03 Medtronic Ave. Extrusion process for coating stents
US20050038497A1 (en) * 2003-08-11 2005-02-17 Scimed Life Systems, Inc. Deformation medical device without material deformation
US20050037048A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices containing antioxidant and therapeutic agent
US20050037052A1 (en) * 2003-08-13 2005-02-17 Medtronic Vascular, Inc. Stent coating with gradient porosity
US20050043786A1 (en) * 2003-08-18 2005-02-24 Medtronic Ave, Inc. Methods and apparatus for treatment of aneurysmal tissue
US20050049693A1 (en) * 2003-08-25 2005-03-03 Medtronic Vascular Inc. Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease
US20050055078A1 (en) * 2003-09-04 2005-03-10 Medtronic Vascular, Inc. Stent with outer slough coating
US20050054774A1 (en) * 2003-09-09 2005-03-10 Scimed Life Systems, Inc. Lubricious coating
US20050055044A1 (en) * 2003-09-09 2005-03-10 Scimed Life Systems, Inc. Lubricious coatings for medical device
US20050060020A1 (en) * 2003-09-17 2005-03-17 Scimed Life Systems, Inc. Covered stent with biologically active material
US20050065593A1 (en) * 2003-09-19 2005-03-24 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US20050065545A1 (en) * 2003-09-23 2005-03-24 Scimed Life Systems, Inc. External activation of vaso-occlusive implants
US20050065501A1 (en) * 2003-09-23 2005-03-24 Scimed Life Systems, Inc. Energy activated vaso-occlusive devices
US20050064088A1 (en) * 2003-09-24 2005-03-24 Scimed Life Systems, Inc Ultrasonic nozzle for coating a medical appliance and method for using an ultrasonic nozzle to coat a medical appliance

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675737B2 (en) 2005-07-25 2017-06-13 Abbott Cardiovascular Systems Inc. Methods of providing antioxidants to a drug containing product
US9655751B2 (en) 2005-07-25 2017-05-23 Abbott Cardiovascular Systems Inc. Kits including implantable medical devices and antioxidants
US20100300903A1 (en) * 2005-07-25 2010-12-02 Ni Ding Methods of providing antioxidants to a drug containing product
US20100300917A1 (en) * 2005-07-25 2010-12-02 Ni Ding Methods of providing antioxidants to a drug containing product
US8128688B2 (en) * 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US20080114096A1 (en) * 2006-11-09 2008-05-15 Hydromer, Inc. Lubricious biopolymeric network compositions and methods of making same
US9033919B2 (en) 2006-11-20 2015-05-19 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8366662B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US8403910B2 (en) 2006-11-20 2013-03-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8404300B2 (en) 2006-11-20 2013-03-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8366660B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8932561B2 (en) 2006-11-20 2015-01-13 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998847B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9005161B2 (en) 2006-11-20 2015-04-14 Lutonix, Inc. Drug releasing coatings for medical devices
US9023371B2 (en) 2006-11-20 2015-05-05 Lutonix, Inc. Drug releasing coatings for medical devices
US9757544B2 (en) 2006-11-20 2017-09-12 Lutonix, Inc. Drug releasing coatings for medical devices
US9737691B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9248220B2 (en) 2006-11-20 2016-02-02 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9283358B2 (en) 2006-11-20 2016-03-15 Lutonix, Inc. Drug releasing coatings for medical devices
US9289537B2 (en) 2006-11-20 2016-03-22 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
US9289539B2 (en) 2006-11-20 2016-03-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9314598B2 (en) 2006-11-20 2016-04-19 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9314552B2 (en) 2006-11-20 2016-04-19 Lutonix, Inc. Drug releasing coatings for medical devices
US9402935B2 (en) 2006-11-20 2016-08-02 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9694111B2 (en) 2006-11-20 2017-07-04 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9764065B2 (en) 2006-11-20 2017-09-19 Lutonix, Inc. Drug releasing coatings for medical devices
US9937159B2 (en) 2006-11-20 2018-04-10 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9757351B2 (en) 2006-11-20 2017-09-12 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
US9770576B2 (en) 2008-08-29 2017-09-26 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9180485B2 (en) 2008-08-29 2015-11-10 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100280594A1 (en) * 2009-05-01 2010-11-04 Medi-Solve, Llc Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
US20110137407A1 (en) * 2009-07-09 2011-06-09 Thai Minh Nguyen Bare metal stent with drug eluting reservoirs
US20130192167A1 (en) * 2010-09-17 2013-08-01 Terumo Kabushiki Kaisha Silicone rubber composition
US9523001B2 (en) * 2010-09-17 2016-12-20 Terumo Kabushiki Kaisha Silicone rubber composition
RU2606436C2 (en) * 2012-03-13 2017-01-10 ТиссенКрупп Рассельштайн ГмбХ Method for treating steel band or plate provided with metal coating with after-treatment agent, and steel band or plate provided with metal coating
US9901663B2 (en) 2013-05-06 2018-02-27 Abbott Cardiovascular Systems Inc. Hollow stent filled with a therapeutic agent formulation

Also Published As

Publication number Publication date
US9675737B2 (en) 2017-06-13
US20100300917A1 (en) 2010-12-02
US20070020380A1 (en) 2007-01-25
US20100300903A1 (en) 2010-12-02
US7785647B2 (en) 2010-08-31
WO2007018931A2 (en) 2007-02-15
WO2007018931A3 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
US8426476B2 (en) Biobeneficial coating compositions and methods of making and using thereof
US7261946B2 (en) Block copolymers of acrylates and methacrylates with fluoroalkenes
US9468706B2 (en) Phosphoryl choline coating compositions
ES2543984T3 (en) Mixtures of poly (ester amide)
JP4863489B2 (en) Bioresorbable coatings and a manufacturing method thereof for an implantable device
JP5684967B2 (en) Hyaluronic acid-based copolymer
US20050208091A1 (en) Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US20050233062A1 (en) Thermal treatment of an implantable medical device
ES2500540T3 (en) Implantable devices that provide controlled release of hydrophobic drugs
US20050112170A1 (en) Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
EP1737505B1 (en) Biologically degradable compositions for coating medical equipment
JP5523670B2 (en) Block copolymers containing coated heparin stent-like implant
US9220815B2 (en) Polymers of fluorinated monomers and hydrocarbon monomers
US8017140B2 (en) Drug-delivery stent formulations for restenosis and vulnerable plaque
US20060115449A1 (en) Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
JP5045746B2 (en) Microporous coating on a medical device
US20050271700A1 (en) Poly(ester amide) coating composition for implantable devices
JP5042211B2 (en) Amorphous poly (d, l-lactide) film
US20060095122A1 (en) Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US7820732B2 (en) Methods for modulating thermal and mechanical properties of coatings on implantable devices
US7699889B2 (en) Poly(ester amide) block copolymers
ES2379574T3 (en) Methacrylate copolymers for medical devices
EP2347776B1 (en) Nanoparticle releasing medical devices
US9993583B2 (en) High-density lipoprotein coated medical devices and methods of treatment using the devices
US20140010858A1 (en) Polymers For Implantable Devices Exhibiting Shape-Memory Effects

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABBOTT CARDIOVASCULAR SYSTEMS INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DING, NI;COLEMAN, LESLIE;REEL/FRAME:019221/0861;SIGNING DATES FROM 20070418 TO 20070423

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION